• / Free eNewsletters & Magazine
  • / My Account
Home>Investing Topics>Regulation

Regulation

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Dialog Semiconductor Plc.: Dialog Semiconductor Enters White Goods Sector with Expanded Power Conversion Product Portfolio (News with Additional Features)

    Dialog Semiconductor Plc.: Dialog Semiconductor Enters White Goods Sector with Expanded Power Conversion Product Portfolio (News with Additional Features)

  2. NYX Gaming Group Limited Reports First Quarter Financial Results

    NYX Gaming Group Limited Reports First Quarter Financial Results

  3. Symphogen’s Antibody Mixtures Highlighted in Three Peer-Reviewed Journals

    Symphogen’s Antibody Mixtures Highlighted in Three Peer-Reviewed Journals

  4. Therma-Flite Thermal Desorption System to Help Multinational O&G Company Reduce Refinery Waste Management Costs

    Therma-Flite Thermal Desorption System to Help Multinational O&G Company Reduce Refinery Waste Management Costs

  5. Darling Ingredients Inc. Announces Private Offering of €515 Million of Unsecured Senior Notes

    Darling Ingredients Inc. Announces Private Offering of €515 Million of Unsecured Senior Notes

  6. Merus Labs to Present at Jefferies 2015 Healthcare Conference in New York

    Merus Labs to Present at Jefferies 2015 Healthcare Conference in New York

  7. Uranium Resources to Divest Roca Honda Property for $2.5 Million Cash and Other Consideration

    Uranium Resources to Divest Roca Honda Property for $2.5 Million Cash and Other Consideration

  8. Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab)

    Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab)

  9. Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for Patients with Two Relapsed/Refractory Blood Cancers

    Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for Patients with Two Relapsed/Refractory Blood Cancers

  10. PetroFrontier Corp. Announces Resignations of Directors

    PetroFrontier Corp. Announces Resignations of Directors

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.